Tools
Stock profile

ANI PHARMACEUTICALS INC (ANIP)

ANIP · Latest close $71.47 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$71.47
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
2
vs previous quarter

ANI PHARMACEUTICALS INC (ANIP) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.0M sold). Latest close $71.47 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-2.0M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Insider trading · 5% holders · Politician trading · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Rubric Capital Management — 1 tracked fund hold ANIP. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 10 sales ($2.0M). Insider trading

Often held alongside

No closely related stocks by co-holding for this stock. Browse all stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Rubric Capital Management0.20%258,131NEW Q3 filed Nov 16
Polen Capital Management——EXITED
Deep Track Capital——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -15.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

98.8151.532024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding304 of 8,857 filers
Long-only filers among them303
Change vs 2026 Q1+32 net · 291 entered · 259 exited
Shares reported, all filers22,898,210
Reported value, all filers$1.9B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$883.4M
Net income · FY2025$78.3M
Total assets · FY2025$1.4B
Shares outstanding22,491,281
Market cap (at latest close)$1.6B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.

Short interest

Shares short · Oct 15, 20263,472,078
Share of shares outstanding15.44%
Days to cover10.10

Shares short at recent settlements — Jul 31, 2026: 2.3M · Aug 14, 2026: 3.4M · Aug 31, 2026: 3.4M · Sep 15, 2026: 2.5M · Sep 30, 2026: 3.5M · Oct 15, 2026: 3.5M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 10 sales by 4 insiders ($2.0M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 13, 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sell500$70.80$35.4KSEC filing
Oct 29, 2026CAREY STEPHEN P.SVP & CFOSell2,850$72.87$207.7KSEC filing
Oct 15, 2026Lalwani NikhilPRESIDENT & CEOSell5,400$71.89$388.2KSEC filing
Oct 13, 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sell500$73.59$36.8KSEC filing
Sep 29, 2026CAREY STEPHEN P.SVP & CFOSell2,850$73.00$208.1KSEC filing
Sep 15, 2026Lalwani NikhilPRESIDENT & CEOSell5,400$71.00$383.4KSEC filing
Sep 14, 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Sell500$70.79$35.4KSEC filing
Sep 11, 2026Thoma JeanneSell1,000$71.53$71.5KSEC filing
Aug 31, 2026CAREY STEPHEN P.SVP & CFOSell2,850$72.80$207.5KSEC filing
Aug 25, 2026Lalwani NikhilPRESIDENT & CEOSell5,400$74.30$401.2KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Aug 22, 2025SCHEDULE 13D/A-22.5% (close Aug 25, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Aug 25, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 27, 2026BlackRock, Inc.SC 13G/A2,899,84312.8%Jun 30, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Nov 13, 2025Integrated Core Strategies (US) LLCSC 13G/A53,7690.2%Sep 30, 2025SEC filing
Oct 17, 2025BlackRock, Inc.SC 13G/A2,517,42411.3%Sep 30, 2025SEC filing
Aug 22, 2025Meridian Venture Partners II GP, L.P. ("GP")SC 13D/A1,014,3814.7%Aug 21, 2025SEC filing
Jun 4, 2025Integrated Core Strategies (US) LLCSC 13G1,108,1275.1%May 30, 2025SEC filing
Apr 10, 2025Millennium Management LLCSC 13G/A818,3413.8%Mar 31, 2025SEC filing
Mar 13, 2025Meridian Venture Partners II GP, L.P. ("GP")SC 13D/A1,164,3815.4%Mar 11, 2025SEC filing
Jan 21, 2025Millennium Management LLCSC 13G1,091,0035.2%Jan 14, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Government relations

Lobbying: 19 Lobbying Disclosure Act filings named this company as client, 2018–2022; most common issues: Medical/Disease Research/Clinical Labs (9), Health Issues (8), Pharmacy (6).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

This stock does not currently pass any tracked screen.

Recent 8-K filings

FiledItemsSource
Nov 16, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Nov 5, 20261.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Nov 5, 20262.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Stocks A–Z · Track Record: how the signals scored · Practice timing on ANIP

One email a week: the week’s new filings and research. Subscribe free

← ANGO  ·  ANL →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.